[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hangzhou Sciwind Biosciences Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":122},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100649290","phase-3-a-study-of-econoglutide-injection-in-obese-participants-with-knee-osteoarthritis-koa-100649290",false,"NCT07734311","A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Ecnoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 28.0 kg\u002Fm\\^2;\n2. The target knee must meet the diagnostic criteria of American College of Rheumatology (ACR) for knee osteoarthritis (clinical and radiological), with moderate radiographic changes (Kellgren-Lawrence grade 2 or 3). The target knee is defined as the knee with the most symptomatic knee at screening period; if pain in both knees are equal, the target knee will be the most dominant leg (preferred leg);\n3. Prior to screening, target knee pain lasting more than 12 weeks, and according to participant's self-report or medical history at screening, target knee pain lasting more than 15 days in the past month;\n4. At screening and prior to randomization, WOMAC pain score (NRS 0-10) of the target knee must be between 4 and 9 (to avoid bias in reporting, participants must not be informed of the pain score used to determine eligibility for the study);\n5. Self-reported by the participant who has a history of unsuccessful weight loss attempt by diet and exercise.\n\nExclusion Criteria:\n\n1. The target knee has undergone joint replacement surgery;\n2. The target knee has undergone arthroscopy within 12 months prior to screening;\n3. At the time of screening, the target knee joint has any clinical features and symptoms of other active infections or crystal-induced arthropathies, as well as any other active joint diseases that may interfere with assessment;\n4. The target knee has received intra-articular injections of hyaluronic acid, any other investigational drugs, or biologics within 3 months prior to screening; or has undergone any procedures that result in persistent sensory loss in the target knee (e.g., ablation) within 6 months prior to screening;\n5. Has received any intramuscular or oral corticosteroids (investigational or marketed) within 30 days prior to screening, or has received any intra-articular corticosteroid injections (investigational or marketed) in any joint within 90 days prior to screening;\n6. History of joint instability in either knee within 12 months prior to screening, such as anterior cruciate ligament rupture or recent trauma;\n7. History of any other potentially causative and\u002For confounding diseases, including Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease-associated arthritis, sarcoidosis, amyloidosis, or fibromyalgia;\n8. Presence of symptomatic hip osteoarthritis at the time of screening, with the exception of those who have undergone hip replacement surgery;\n9. Conditions that may interfere with the assessment of target knee pain during screening include, but are not limited to:\n\n   * Pain in any part of the lower limb or back equal to or more severe than the pain in the target knee;\n   * Pain radiating to the knee from other areas, such as hip pain affecting the knee or radicular pain;\n   * Chronic widespread pain (including neuropathic pain);\n10. Change of body weight \\>5% within 3 months prior to screening (selfreported);\n11. Diagnosis of diabetes (excluding gestational diabetes), or with a history of diabetic ketoacidosis or hyperosmolar state\u002Fcoma","ALL","18 Years","75 Years",{"count":20,"type":21},360,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.",[27,28],"Knee Osteoarthritis","Obesity",[30,31,28],"Ecnoglutide","KOA","NOT_YET_RECRUITING","2026-07-24",{"date":35,"type":36},"2026-07-29","ACTUAL",{"date":38,"type":21},"2026-07-31",{"date":40,"type":21},"2028-06-30",{"name":42,"class":43},"Hangzhou Sciwind Biosciences Co., Ltd.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100626316","phase-3-a-study-of-xw003-in-obese-participants-with-obstructive-sleep-apnea-receiving-positive-airway-pressure-therapy-100626316","NCT07434050","A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 28.0 kg\u002Fm2;\n2. The results of PSG meet the diagnosis criteria of OSA and with an AHI≥15 at screening;\n3. Have been on PAP therapy for at least 3 consecutive months prior to screening and plan to continue PAP therapy during the study;\n4. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. History of endocrine disorders which have significant impact on body weight;\n2. Diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state\u002Fcoma;\n3. HbA1c ≥6.5% at screening;\n4. Fasting blood glucose ≥7.0 mmol\u002FL or 2-hour blood glucose ≥11.1 mmol\u002FL after oral glucose tolerance test (OGTT) at screening; participants with FBG ≥6.1 mmol\u002FL but \\\u003C7.0 mmol\u002FL require OGTT;\n5. Have diagnosis of Cheyne Stokes Respiration, or diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas\u002Fhypopneas ≥50%;\n6. Respiratory and neuromuscular diseases that could interfere with the results of the trial;\n7. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia;\n8. Change of body weight \\>5% within 3 months prior to screening (selfreported);\n9. Have a prior or planned surgical treatment for obesity (except liposuction or abdominoplasty if performed more than 1 year prior to screening);\n10. Have received any medication for body weight loss and blood glucose lowering or medication that could lead to significant body weight increase, within 3 months prior to screening.",{"count":53,"type":21},140,[24],"The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP",[57,28],"OSA - Obstructive Sleep Apnea",[59,30,60,28,61],"XW003","OSA","GLP-1","RECRUITING","2026-04-09",{"date":65,"type":36},"2026-04-13",{"date":67,"type":36},"2026-03-02",{"date":69,"type":21},"2028-06-19",{"name":42,"class":43},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":44},"100622705","phase-3-a-study-of-xw003-in-obese-participants-with-obstructive-sleep-apnea-but-not-receive-positive-airway-pressure-therapy-100622705","NCT07387094","A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy","Inclusion Criteria:\n\n1. Body mass index (BMI) ≥ 28.0 kg\u002Fm2;\n2. The results of PSG meet the diagnosis criteria of OSA and with an AHI ≥15 at screening;\n3. Participants must not have used PAP for at least 4 weeks prior to screening and not use PAP during the study;\n4. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. History of endocrine disorders which have significant impact on body weight;\n2. Diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state\u002Fcoma;\n3. HbA1c ≥6.5% at screening;\n4. Fasting blood glucose ≥7.0 mmol\u002FL or 2-hour blood glucose ≥11.1 mmol\u002FL after oral glucose tolerance test (OGTT) at screening; participants with FBG ≥6.1 mmol\u002FL but \\\u003C7.0 mmol\u002FL require OGTT;\n5. Have diagnosis of Cheyne Stokes Respiration, or diagnosis of Central or Mixed Sleep Apnea with % of mixed or central apneas\u002Fhypopneas ≥50%;\n6. Respiratory and neuromuscular diseases that could interfere with the results of the trial;\n7. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia;\n8. Change of body weight \\>5% within 3 months prior to screening (self-reported);\n9. Have a prior or planned surgical treatment for obesity (except liposuction or abdominoplasty if performed more than 1 year prior to screening);\n10. Have received any medication for body weight loss and blood glucose lowering or medication that could lead to significant body weight increase, within 3 months prior to screening.",{"count":53,"type":21},[24],"The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAP",[57,28],[59,30,28,60,61],{"date":84,"type":36},"2026-04-14",{"date":86,"type":36},"2026-02-09",{"date":88,"type":21},"2027-12-16",{"name":42,"class":43},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":44},"100611637","phase-1-a-phase-ibiia-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-oral-ecnoglutide-tablets-in-chinese-participants-with-overweight-or-obesity-100611637","NCT07243171","A Phase Ib\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity","A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity","Inclusion Criteria:\n\n1. At the time of informed consent, with BMI in the range of 24.0 to 35.0 kg\u002Fm2 (including the threshold), body weight \\>60.0 kg for male, and weight \\>50.0 kg for female;\n2. Self-declaration of body weight change \\\u003C5% within 3 months prior to informed consent ;\n\nExclusion Criteria:\n\n1. Diagnosis of overweight or obesity due to endocrine disorders , such as Cushing's syndrome;\n2. Diagnosis of other endocrine disorders with clinical significance, including but not limited to hyperthyroidism or hypothyroidism, thyroid nodules (imaging shows TI-RADS≥ class 3), thyroid cancer, or personal or family history of type 2 multiple endocrine tumor syndrome (MEN2), etc.\n3. Diagnosis of cardiovascular or cerebrovascular diseases with clinical significance within 6 months prior to screening, including but not limited to acute stroke, acute coronary syndrome, heart failure, arrhythmia, etc.\n4. Diagnosis of severe gastrointestinal diseases, including but not limited to inflammatory bowel disease, active ulcers, irritable bowel syndrome, celiac disease, dyspepsia, diabetic gastroparesis, diabetic diarrhea, clinical gastric emptying abnormalities (such as pyloric obstruction), etc.\n5. History of major gastrointestinal surgery (except cholecystectomy or appendectomy), or metabolic surgery, or plan to undergo major surgery during the study period;\n6. HbA1c ≥6.5% or fasting blood glucose ≥7.0 mmol\u002FL, or OGTT 2-hour blood glucose ≥11.1 mmol\u002FL, at screening;\n7. Clinical laboratory test results with clinical significance",true,"65 Years",{"count":100,"type":21},84,[102,103],"PHASE1","PHASE2","The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity",[106,107],"Overweight and\u002For Obesity","Weight Management",[109,110,111,112,113],"ecnoglutide","glucagon-like peptide-1 (GLP-1)","obesity","overweight","weight management","2026-01-27",{"date":116,"type":36},"2026-01-28",{"date":118,"type":36},"2025-11-18",{"date":120,"type":21},"2026-11-22",{"name":42,"class":43},""]